25 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Bristol Myers' Applications for Opdivo-Yervoy Combo Accepted http://www.zacks.com/stock/news/862804/bristol-myers-applications-for-opdivo-yervoy-combo-accepted?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-862804 Apr 09, 2020 - Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.
Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review http://www.zacks.com/stock/news/876410/regenerons-bla-for-ebola-vaccine-gets-fdas-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-876410 Apr 17, 2020 - The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.
Earnings Data Deluge http://www.zacks.com/stock/news/893984/earnings-data-deluge?cid=CS-ZC--economic_highlights-893984 Apr 28, 2020 - Earnings Data Deluge
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-ZC-FT-analyst_blog|rank_focused-851267 Apr 02, 2020 - Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
Why Merck (MRK) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/853066/why-merck-mrk-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-853066 Apr 03, 2020 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates http://www.zacks.com/stock/news/853058/pharma-stock-roundup-jnj-snys-coronavirus-product-development-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-853058 Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Top Stock Reports for J&J, Merck, Novartis & Others http://www.zacks.com/research-daily/857167/top-stock-reports-for-jj-merck-novartis-others?cid=CS-ZC-FT-research_daily-857167 Apr 06, 2020 - Top Stock Reports for J&J, Merck, Novartis & Others
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result? http://www.zacks.com/stock/news/868906/will-jjs-pharma-unit-perform-above-market-to-drive-q1-result?cid=CS-ZC-FT-analyst_blog|earnings_preview-868906 Apr 13, 2020 - J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
AstraZeneca's Koselugo Gets FDA Nod for Rare Genetic Disorder http://www.zacks.com/stock/news/868925/astrazenecas-koselugo-gets-fda-nod-for-rare-genetic-disorder?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-868925 Apr 13, 2020 - The FDA approves AstraZeneca (AZN) and Merck's kinase inhibitor, Koselugo, for treating pediatric patients with neurofibromatosis type 1 (NF1) having symptomatic, inoperable plexiform neurofibromas.
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre http://www.zacks.com/stock/news/880319/incyte-gets-fda-nod-for-cholangiocarcinoma-drug-pemazyre?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-880319 Apr 20, 2020 - Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.

Pages: 123

<Page 2